Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET

LAVAL, QC, Dec. 15 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) will host a webcast presentation on, Tuesday, December 16, 2008, at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory progress and the market opportunity for its novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder.

The live audio webcast will be available at Please connect at least 15 minutes prior to the start time to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

To access the webcast via telephone conference call (required to participate in Q&A), dial 416-644-3414 or 1-800-733-7560. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Tuesday, December 23, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21289816 followed by the number sign.

The webcast will also include presentations by two leading experts in the treatment of depression. Dr. Steven M. Stahl, adjunct Professor of Psychiatry at the University of California, San Diego, School of Medicine, will discuss the mechanism of action of trazodone and the value of SARIs in the treatment of depression. Dr. David V. Sheehan, Distinguished University Health Professor and Director of the Depression and Anxiety Disorders Research Institute at the University of South Florida College of Medicine, will review the clinical data from Labopharm's positive Phase III clinical trial for its novel trazodone formulation, including a presentation of additional data.

About the Presenters

Dr. Stahl has conducted numerous research projects during his career and is awarded by the National Institute of Mental Health, by the Veterans Administration, and by the pharmaceutical industry. Author of more than 350 articles and chapters, Dr. Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best-selling clinical manual, Essential Psychopharmacology Prescriber's Guide.

Dr. Sheehan has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry, the International Academy for Biomedical and Drug Research, the US Food and Drug Administration, and a research grant reviewer for the National Institute for Mental Health (NIMH). Dr. Sheehan has been invited to give over 1600 lectures in 64 countries throughout the world on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association.

    About Labopharm's Novel Trazodone Formulation and the Market for

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
Breaking Medicine Technology: